KalshiVerfügbarkeit prüfenKYC erforderlichVerifizierte AuflösungsdatenGut kalibriertMittelwert des gewählten Orderbuchs
Before Jan 1, 2029 · —
Gewähltes Orderbuch wird geladen…
—
Gespeicherter Preis
Before Jan 1, 2029 89.5%Führend unter 5 Optionen
Before Jan 1, 2029 89.5%Marktqualitat
59 / 100
Mittlere Qualität24h-Volumen
46,9 €
Open Interest
24.448,7 $
Mittleres Open InterestGeld / Brief
— / —
Before Jan 1, 2029Spread
—
Marktdaten
Aktualisiert vor 10 Minuten
14. Mai 26, 02:00 UTC1. Jan. 27, 15:00 UTC
Chart und Änderungen zeigen gespeicherte historische Wahrscheinlichkeiten, nicht das gewählte aktuelle Orderbuch.
Trends
Gewählte Zeile: Orderbuch-Mittelwert. Andere Zeilen: gespeicherte, ggf. normalisierte Referenzwerte; 24h-Änderungen basieren auf gespeicherter Historie.
Handelsplatzbedingungen
Quelle: Kalshi
Diese Angaben dienen der Information; für den simulierten Handel bei CoinRithm gelten eigene Regeln.
- Vorzeitige Schließung:
- Ja
- Abrechnungsfrist:
- 30m (unverbindliche Angabe)
Markttiefe · Before Jan 1, 2029
Gewähltes Orderbuch wird geladen…
—
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
When will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill the FDA approve a cure for Type 1 diabetes before 2033?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsRegeln
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Abwicklung über:Food and Drug Administration
Regeln für jedes Ergebnis
- Before Jan 1, 2029
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
